Amplification of epidermal growth factor receptor gene in renal cell carcinoma

European Journal of Cancer

Volumn 46, Issue 5, 2010, Pages 859-862

  El Hariry, Iman ^a   Powles, Thomas ^b   Lau, Mike R ^a   Sternberg, Cora N ^c   Ravaud, Alain ^d   von der Maase, Hans ^e   Zantl, Niko ^f   Harper, Peter ^g   Rolland, Frédéric ^h   Audhuy, Bruno ⁱ   Barthel, Friederike ^a   Machiels, Jean Pascal ^j   Patel, Pina ^k   Kreuser, Ernst Dietrick ^l   Hawkins, Robert E ^m  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e Mental Health Services CPH   (Denmark)

^f KLINIKUM KONSTANZ   (Germany)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h CENTRE RENÉ GAUDUCHEAU   (France)

ⁱ Pasteur Hospital   (France)

^j UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^k UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^l KRANKENHAUS BARMHERZIGE BRÜDER   (Germany)

^m CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

Epidermal growth factor receptor; Fluorescent in situ hybridisation; Renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 77349114402     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.01.011     Document Type: Article

References (19)

1. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 8 (1999) 2530-2540
2. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol 24 35 (2006) 5593-5600
3. Atkins D.J., Gingert C., Justenhoven C., et al. Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas. Virchows Arch 447 3 (2005) 634-642
4. Escudier B. Anti-VEGF therapy for renal cell carcinoma. Clin Adv Hematol Oncol 5 7 (2007) 530-531
5. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [see comment]. Lancet 370 9605 (2007) 2103-2111
6. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [see comment]. N Engl J Med 356 2 (2007) 115-124
7. Smith K., Gunaratnam L., Morley M., et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res 65 12 (2005) 5221-5230
8. Stumm G., Eberwein S., Rostock-Wolf S., et al. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer 69 1 (1996) 17-22
9. Dawson N.A., Guo C., Zak R., et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10 23 (2004) 7812-7819
10. Ravaud A., Hawkins R., Gardner J.P., et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 26 14 (2008) 2285-2291
11. Dziadziuszko R., Hirsch F.R., Varella-Garcia M., and Bunn Jr. P.A. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization-why, when, and how?. Clin Cancer Res 12 14 pt 2 (2006) 4409s-4415s
12. Hirsch F.R., Varella-Garcia M., McCoy J., et al. Southwest Oncology, G. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study [see comment]. J Clin Oncol 23 28 (2005) 6838-6845
13. Moch H., Sauter G., Gasser T.C., et al. EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. J Pathol 184 4 (1998) 424-429
14. Hirsch F.R., Varella-Garcia M., Cappuzzo F., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18 4 (2007) 752-760
15. Jeon Y.K., Sung S.-W., Chung J.-H., et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung cancer 54 3 (2006) 387-398
16. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [see comment]. N Engl J Med 350 21 (2004) 2129-2139
17. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [see comment]. Science 304 5676 (2004) 1497-1500
18. Yatabe Y., Takahashi T., and Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68 7 (2008) 2106-2111
19. Sakaeda T., Okamura N., Gotoh A., et al. EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. Pharm Res 22 10 (2005) 1757-1761